Relmada (RLMD) Q4 2025 earnings review
Runway Secured to 2029, But the Cost is Staggering Dilution
Relmada has successfully completed its strategic pivot from CNS to oncology, backed by highly durable 12-month Phase 2 data for NDV-01. The Complete Response (CR) rate of 80% at 12 months for BCG-unresponsive patients is exceptional. To capitalize on this, management orchestrated a massive recapitalization—a $94M offering in late 2025 followed by an oversubscribed $160M PIPE in March 2026. This extends the cash runway into 2029 and fully funds the Phase 3 RESCUE program. However, this survival comes at a severe cost to existing shareholders: outstanding shares exploded from 30M to 73M even before the $160M PIPE is accounted for. Meanwhile, operating expenses are sharply reversing their previous downward trend as trial preparation begins.
🐂 Bull Case
Ending the year with $93M and adding a $160M PIPE in Q1 2026 secures the balance sheet through 2029. This removes all near-term financing overhangs in a challenging biotech macro environment.
The 12-month NDV-01 data shows remarkable durability. A 76% CR rate at 12 months (80% for BCG-unresponsive) with zero progression to muscle-invasive disease strongly validates the asset's best-in-class potential.
🐻 Bear Case
Outstanding shares jumped 143% YoY to 73.3M by year-end 2025. The additional $160M PIPE will dilute legacy shareholders even further, capping the per-share upside of the clinical success.
Management's narrative of 'financial discipline' in mid-2025 is over. Q4 G&A spiked 52% YoY to $12.3M, and R&D doubled sequentially. The cash burn will only intensify as Phase 3 initiates.
⚖️ Verdict: ⚪
Neutral. The asset (NDV-01) is clearly working and the company is fully funded, which is a rare luxury for clinical-stage biotechs. However, the extreme dilution fundamentally alters the equity math, and execution risk is about to rise as Phase 3 begins.
Key Themes
NDV-01 Sustained Efficacy and Innovation
The 12-month Phase 2 data confirms the viability of Relmada's 'soft matrix' sustained-release formulation. By allowing gradual release of Gemcitabine/Docetaxel over 10 days via a simple 5-minute in-office procedure, it yielded a 95% CR at any time and 76% at 12 months. Crucially, in the hardest-to-treat BCG-unresponsive cohort, the 12-month CR was 80%. This technological innovation directly translates into sustained clinical outcomes with no Grade 3+ treatment-related adverse events.
De-Risked Regulatory Pathways (RESCUE)
Relmada has secured FDA alignment on two parallel Phase 3 paths for the 'RESCUE' program. Pathway 1 addresses a ~75,000 patient/year market (Adjuvant Intermediate-Risk) via a randomized trial. Pathway 2 addresses the immediate unmet need of 2L BCG-unresponsive patients (~5,000/year) via a potentially faster single-arm trial. This dual-track approach mitigates regulatory risk.
Massive Balance Sheet Fortification
Raising capital is the hardest macro challenge for clinical-stage biotechs right now. Relmada defied the macro environment by closing a $94M offering and a heavily oversubscribed $160M PIPE led by 'leading healthcare investors.' With a pro-forma cash position exceeding $250M, Relmada has secured its operations through 2029, entirely funding the Phase 3 program to completion.
Unprecedented Dilution Cycle
The cost of survival has been steep. Shares outstanding skyrocketed from 30.1M in Q4 2024 to 73.3M by Q4 2025. This does not even account for the shares issued in the $160M March 2026 PIPE. While the enterprise value is protected by cash, legacy shareholders own a fraction of the company they did a year ago.
G&A Expense Spike Contradicts Cost-Control Narrative
Throughout early 2025, management touted sharp reductions in operating burn due to the wind-down of previous CNS trials. However, Q4 G&A expenses reversed course dramatically, jumping to $12.3M (up 52% YoY and 95% sequentially from Q3). While R&D increases are expected for Phase 3 prep, a massive G&A spike requires scrutiny regarding corporate overhead and compensation structures.
Execution Risk in a New Modality
Relmada is officially an oncology company now, having left its CNS roots behind. Launching the Phase 3 RESCUE program and a separate Phase 2 trial for Sepranolone simultaneously in mid-2026 will test a management team operating in therapeutic areas where they have no historical commercial track record.
Other KPIs
Accelerating. The net loss widened from $10.1 million in Q3 2025 to $19.9 million in Q4 2025. For the full year, net loss was $57.4 million, an improvement from $80.0 million in 2024, but the quarterly trajectory shows burn is ramping back up.
Stable compared to FY24 (-$51.8 million). However, Q4 saw a sharp sequential uptick in cash used in operations ($14.6 million vs $6.7 million in Q3), reflecting the upfront costs of acquiring clinical trial sites and manufacturing scale-up for NDV-01.
Accelerating dramatically. Up from $13.9 million at the end of Q3 2025, thanks to the $94 million November offering. Adding the $160 million March 2026 PIPE fundamentally changes the financial profile of the company.
Guidance
Accelerating. Previous guidance in Q3 projected cash into 2028. The additional $160M PIPE extends this by a full year, ensuring the company does not need to return to the equity markets before Phase 3 RESCUE completion.
Stable. The company remains on track with prior commentary to initiate the registrational studies in the first half/mid of 2026 following US IND clearance.
New guidance. The company expects initial 3-month data from the 2L BCG-unresponsive study by year-end 2026. This provides a critical near-term catalyst to maintain momentum while the longer intermediate-risk trial enrolls.
Key Questions
G&A Expense Clarification
G&A spiked to $12.3 million in Q4, up over 50% year-over-year. How much of this increase was one-time transaction costs related to the November offering versus structural overhead, and what is the baseline G&A run-rate for 2026?
Fully Diluted Share Count
With outstanding shares hitting 73.3 million at year-end, what is the pro-forma fully diluted share count following the $160 million PIPE in March 2026?
Phase 3 Enrollment Velocity
Given the lack of approved therapies for intermediate-risk NMIBC, what are your assumptions for monthly patient enrollment rates in Pathway 1, and how does that inform the timeline to full data readout?